European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience

A. T. van der Ploeg, M. E. Kruijshaar, A. Toscano, P. Laforêt, C. Angelini, R. H. Lachmann, S. I. Pascual Pascual, M. Roberts, K. Rösler, T. Stulnig, P. A. van Doorn, P. Y.K. Van den Bergh, J. Vissing, B. Schoser, Bruno Bembi, Alexander Broomfield, Matthias Boentert, Claude Desnuelle, Oliver Findling, Andreas HahnJordi Díaz-Manera, Thomas Hundsberger, Cornelia Kornblum, Franҫois Labarthé, Pascal Laforet, Karl Eugen Mengel, Tiziana Mongini, Wolfgang Muller-Felber, Giancarlo Parenti, W. Pim Pijnappel, Nicolai Preisler, Sabrina Sacconi, Beril Talim, Marine Tardieu, Nadine A.M.E. van der Beek, Stephan Wenninger, the European Pompe Consortium

Research output: Contribution to journalArticle

Abstract

Background and purpose: Pompe disease is a rare inheritable muscle disorder for which enzyme replacement therapy (ERT) has been available since 2006. Uniform criteria for starting and stopping ERT in adult patients were developed and reported here. Methods: Three consensus meetings were organized through the European Pompe Consortium, a network of experts from 11 European countries in the field of Pompe disease. A systematic review of the literature was undertaken to determine the effectiveness of ERT in adult patients on a range of clinical outcome measures and quality of life. A narrative synthesis is presented. Results: Consensus was reached on how the diagnosis of Pompe disease should be confirmed, when treatment should be started, reasons for stopping treatment and the use of ERT during pregnancy. This was based on expert opinion and supported by the literature. One clinical trial and 43 observational studies, covering a total of 586 individual adult patients, provided evidence of a beneficial effect of ERT at group level. At individual patient level, the response to treatment varied, but factors associated with a patient's response to ERT were not described in many studies. Eleven observational studies focused on more severely affected patients, suggesting that ERT can also be beneficial in these patients. There are no studies on the effects of ERT in pre-symptomatic patients. Conclusions: This is the first European consensus recommendation for starting and stopping ERT in adult patients with Pompe disease, based on the extensive experience of experts from different countries.

Original languageEnglish
Pages (from-to)768-e31
JournalEuropean Journal of Neurology
Volume24
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Keywords

  • adult patients
  • alglucosidase alfa
  • enzyme replacement therapy
  • guidelines
  • Pompe disease
  • treatment recommendations

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience'. Together they form a unique fingerprint.

  • Cite this

    van der Ploeg, A. T., Kruijshaar, M. E., Toscano, A., Laforêt, P., Angelini, C., Lachmann, R. H., Pascual Pascual, S. I., Roberts, M., Rösler, K., Stulnig, T., van Doorn, P. A., Van den Bergh, P. Y. K., Vissing, J., Schoser, B., Bembi, B., Broomfield, A., Boentert, M., Desnuelle, C., Findling, O., ... the European Pompe Consortium (2017). European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. European Journal of Neurology, 24(6), 768-e31. https://doi.org/10.1111/ene.13285